Alimta ANDA Products Hit Double Digits With Several Launches
Fresenius Kabi Has ‘Broadest Portfolio Available’
Executive Summary
Following patent expiry on 24 May, Alimta ANDA products have reached the US market, eating into a product that generated more than $1.2bn in sales last year.
You may also be interested in...
Amneal Lines Up Ready-To-Use Pemetrexed Hybrid
Amneal has set a launch date for its ready-to-use presentation of pemetrexed after the FDA approved the 505(b)(2) product under the name of Pemrydi.
Waverley Weighs Its Options With High Costs, Thin Margins
Waverley is evaluating options for its generics as it looks likely to throw its all at the company’s lead product candidate in the hopes of luring a development partner or buyer.
Dr Reddy’s Follows Viatris With Second US Nexavar Rival
Hot on the heels of the first US generic Nexavar launch by Viatris, Dr Reddy’s has followed with a second sorafenib rival. The product represents the latest in a string of significant US launches for the Indian company.